Matched-pair analysis of patients with female and male breast cancer: a comparative analysis

<p>Abstract</p> <p>Background</p> <p>Male breast cancer (MBC) is a rare disease accounting for approximately 1% of all breast carcinomas. Presently treatment recommendations are derived from the standards for female breast cancer. However, those approaches might be inad...

Full description

Bibliographic Details
Main Authors: Kuhn Walther C, Wolfgarten Matthias, Baaske Dieter, Schubotz Birgit, Wulff Volkhard, Foerster Frank G, Foerster Robert, Rudlowski Christian
Format: Article
Language:English
Published: BMC 2011-08-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/11/335
id doaj-09dc23fc62734c78a614e70bb347159e
record_format Article
spelling doaj-09dc23fc62734c78a614e70bb347159e2020-11-24T20:56:04ZengBMCBMC Cancer1471-24072011-08-0111133510.1186/1471-2407-11-335Matched-pair analysis of patients with female and male breast cancer: a comparative analysisKuhn Walther CWolfgarten MatthiasBaaske DieterSchubotz BirgitWulff VolkhardFoerster Frank GFoerster RobertRudlowski Christian<p>Abstract</p> <p>Background</p> <p>Male breast cancer (MBC) is a rare disease accounting for approximately 1% of all breast carcinomas. Presently treatment recommendations are derived from the standards for female breast cancer. However, those approaches might be inadequate because of distinct gender specific differences in tumor biology of breast cancer. This study was planned in order to contrast potential differences between female and male breast cancer in both tumor biological behavior and clinical management.</p> <p>Methods</p> <p>MBC diagnosed between 1995-2007 (region Chemnitz/Zwickau, Saxony, Germany) was retrospectively analyzed. Tumor characteristics, treatment and follow-up of the patients were documented. In order to highlight potential differences each MBC was matched with a female counterpart (FBC) that showed accordance in at least eight tumor characteristics (year of diagnosis, age, tumor stage, nodal status, grade, estrogen- and progesterone receptors, HER2 status).</p> <p>Results</p> <p>108 male/female matched-pairs were available for survival analyses. In our study men and women with breast cancer had similar disease-free (DFS) and overall (OS) survival. The 5-years DFS was 53.4% (95% CI, range 54.1-66.3) in men respectively 62.6% (95% CI, 63.5-75.3) in women (p > 0.05). The 5-years OS was 71.4% (95% CI, 62.1-72.7%) and 70.3% (95% CI, 32.6-49.6) in women (p > 0.05). In males DFS analyses revealed progesterone receptor expression as the only prognostic relevant factor (p = 0.006). In multivariate analyses for OS both advanced tumor size (p = 0.01) and a lack of progesterone receptor expression were correlated (p = 0.01) with poor patients outcome in MBC.</p> <p>Conclusion</p> <p>Our comparative study revealed no survival differences between male and female breast cancer patients and gives evidence that gender is no predictor for survival in breast cancer. This was shown despite of significant gender specific differences in terms of frequency and intensity of systemic therapy in favor to female breast cancer.</p> http://www.biomedcentral.com/1471-2407/11/335
collection DOAJ
language English
format Article
sources DOAJ
author Kuhn Walther C
Wolfgarten Matthias
Baaske Dieter
Schubotz Birgit
Wulff Volkhard
Foerster Frank G
Foerster Robert
Rudlowski Christian
spellingShingle Kuhn Walther C
Wolfgarten Matthias
Baaske Dieter
Schubotz Birgit
Wulff Volkhard
Foerster Frank G
Foerster Robert
Rudlowski Christian
Matched-pair analysis of patients with female and male breast cancer: a comparative analysis
BMC Cancer
author_facet Kuhn Walther C
Wolfgarten Matthias
Baaske Dieter
Schubotz Birgit
Wulff Volkhard
Foerster Frank G
Foerster Robert
Rudlowski Christian
author_sort Kuhn Walther C
title Matched-pair analysis of patients with female and male breast cancer: a comparative analysis
title_short Matched-pair analysis of patients with female and male breast cancer: a comparative analysis
title_full Matched-pair analysis of patients with female and male breast cancer: a comparative analysis
title_fullStr Matched-pair analysis of patients with female and male breast cancer: a comparative analysis
title_full_unstemmed Matched-pair analysis of patients with female and male breast cancer: a comparative analysis
title_sort matched-pair analysis of patients with female and male breast cancer: a comparative analysis
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2011-08-01
description <p>Abstract</p> <p>Background</p> <p>Male breast cancer (MBC) is a rare disease accounting for approximately 1% of all breast carcinomas. Presently treatment recommendations are derived from the standards for female breast cancer. However, those approaches might be inadequate because of distinct gender specific differences in tumor biology of breast cancer. This study was planned in order to contrast potential differences between female and male breast cancer in both tumor biological behavior and clinical management.</p> <p>Methods</p> <p>MBC diagnosed between 1995-2007 (region Chemnitz/Zwickau, Saxony, Germany) was retrospectively analyzed. Tumor characteristics, treatment and follow-up of the patients were documented. In order to highlight potential differences each MBC was matched with a female counterpart (FBC) that showed accordance in at least eight tumor characteristics (year of diagnosis, age, tumor stage, nodal status, grade, estrogen- and progesterone receptors, HER2 status).</p> <p>Results</p> <p>108 male/female matched-pairs were available for survival analyses. In our study men and women with breast cancer had similar disease-free (DFS) and overall (OS) survival. The 5-years DFS was 53.4% (95% CI, range 54.1-66.3) in men respectively 62.6% (95% CI, 63.5-75.3) in women (p > 0.05). The 5-years OS was 71.4% (95% CI, 62.1-72.7%) and 70.3% (95% CI, 32.6-49.6) in women (p > 0.05). In males DFS analyses revealed progesterone receptor expression as the only prognostic relevant factor (p = 0.006). In multivariate analyses for OS both advanced tumor size (p = 0.01) and a lack of progesterone receptor expression were correlated (p = 0.01) with poor patients outcome in MBC.</p> <p>Conclusion</p> <p>Our comparative study revealed no survival differences between male and female breast cancer patients and gives evidence that gender is no predictor for survival in breast cancer. This was shown despite of significant gender specific differences in terms of frequency and intensity of systemic therapy in favor to female breast cancer.</p>
url http://www.biomedcentral.com/1471-2407/11/335
work_keys_str_mv AT kuhnwaltherc matchedpairanalysisofpatientswithfemaleandmalebreastcanceracomparativeanalysis
AT wolfgartenmatthias matchedpairanalysisofpatientswithfemaleandmalebreastcanceracomparativeanalysis
AT baaskedieter matchedpairanalysisofpatientswithfemaleandmalebreastcanceracomparativeanalysis
AT schubotzbirgit matchedpairanalysisofpatientswithfemaleandmalebreastcanceracomparativeanalysis
AT wulffvolkhard matchedpairanalysisofpatientswithfemaleandmalebreastcanceracomparativeanalysis
AT foersterfrankg matchedpairanalysisofpatientswithfemaleandmalebreastcanceracomparativeanalysis
AT foersterrobert matchedpairanalysisofpatientswithfemaleandmalebreastcanceracomparativeanalysis
AT rudlowskichristian matchedpairanalysisofpatientswithfemaleandmalebreastcanceracomparativeanalysis
_version_ 1716790910896832512